Category Archives: Genetic Research

New genetic variants influencing Body Mass Index, Weight, and risk of Obesity

deCODE scientists have discovered new genetic variants influencing BMI, weight and risk of obesity

deCODE scientists have discovered new genetic variants influencing BMI, weight and risk of obesity

As we all know to well, for decades the scales have been tipping in favor of obesity. The epidemic of obesity in many industrialized countries has been driven by many factors, including easy access to fast food, an increasingly sedentary lifestyle, insufficient daily physical activity. All of this while our genomes have evolved on a background of scarcity, often putting a premium on the ability of the body to turn food into fat and store energy for leaner times. A paper published today by deCODE scientists and academic colleagues from the US and Europe provide a significant advance in our knowledge of the underlying genetics and biology of obesity, providing new information for understanding and addressing obesity and perhaps nudging the scales the other way.
Read More »

No responses yet   |   Bookmark and Share   |   Tags: , , , , , .

deCODE to Integrate New Genetic Risk Factor for Type 2 Diabetes into its deCODEme™ Personal Genome Scan Service

Prince Joachim of Denmark and Princess Marie of Denmark along with deCODE scientist Unnur Thorsteinsdottir during an official visit to deCODE laboratories earlier this year

Crown Prince Frederik of Denmark and Crown Princess Marie of Denmark along with deCODE scientist Unnur Thorsteinsdottir during an official visit to deCODE laboratories earlier this year.

Reykjavik, ICELAND, December 8, 2008 – deCODE genetics (Nasdaq:DCGN) today announced the discovery by an international consortium of scientists from deCODE and major European and US academic institutions of a single letter variation in the human genome (SNP) that is associated with increased fasting glucose levels and risk of type 2 diabetes (T2D). deCODE will employ its CLIA-registered genotyping laboratory and existing testing platform to swiftly integrate the finding into its deCODEme™ personal genome scan, and to assess the addition of this new variant to the company’s deCODE T2™ reference laboratory test for assessing individual risk of type 2 diabetes.
Read More »

No responses yet   |   Bookmark and Share   |   Tags: , , , , , , , .

The battle against breast cancer gets personalized

deCODE Breast Cancer enables women to understand whether they may benefit from more intensive screening, monitoring or preventive drug therapy.

A new genetic test assessing a woman's risk of developing the most common forms of breast cancer has arrived. Can the test, developed by the biopharmaceutical company deCODE, improve the way doctors screen for breast cancer?

Breast cancer kills 40,000 people a year in the U.S. This is about the population of Atlantic City, New Jersey. Imagine, each year an entire city wiped out by breast cancer.

To help fight breast cancer, a new test assessing individual risk has just become available. For women without a clear family history of the disease, the deCODE BreastCancerTM test assesses their personal risk of developing the most common forms of breast cancer. The DNA test, launched by the biopharmaceutical company deCODE, makes it possible to identify those women at significantly higher than average risk, helping doctors use new screening technologies and treatments in a more targeted, personalized and effective manner.

Read More »

No responses yet   |   Bookmark and Share   |   Tags: , , , .

The Breast Cancer Network of Strength celebrates 30 years of invaluable support

Breast Cancer Network of Strength was started by Mimi Kaplan and Ann Marcou

Breast Cancer Network of Strength was started by Mimi Kaplan and Ann Marcou.

Attitudes towards breast cancer have changed quite a lot over the past three decades, a fact evidenced by the outpouring of response when stars such as Olivia Newton-John, Kylie Minogue, and, most recently, Christina Applegate, went public with their personal struggles with the disease. But this change in attitude is also reflected in many other ways and not least in the adoption of a new name for the patient advocacy and support organization that until now called itself Y-ME? Tomorrow, a gala event held at the Fairmont Hotel in Chicago will celebrate Breast Cancer Awareness Month and the evolution of Y-ME, 30 years on, into the Breast Cancer Network of Strength-a change they hope that will better communicate the organization’s mission to promote a proactive, engaged and positive approach to fighting breast cancer.

Read More »

No responses yet   |   Bookmark and Share   |   Tags: , , , , , , .

Breast cancer gene tests explained

On October 8th MSNBC published an article by Arthur Caplan, Ph.D. on genetic tests for breast cancer.
The following is a response by Jeff Gulcher, M.D., Ph.D, Chief Scientific Officer at deCODE Genetics.

Arthur Caplan stresses caution in the application of the new genetic risk tests for common diseases and I certainly agree that genetic testing should be applied with care. However, he goes too far when he says that the new deCODE BreastCancer genetic risk test is only useful for women who have two or more close relatives with breast cancer, is not based on large enough studies to be accurate, and is not regulated.

There are two major types of breast cancer: the rare, early onset form that occurs in certain families and for the detection (for which the Myriad Genetic test is well suited), and the common form which accounts for 95 percent of breast cancer. The vast majority of women who develop breast cancer do not have the conventional risk factors of family history, pregnancy history or breast density. Unfortunately, many of these women were likely considered to be of average risk before their cancer was found. Therefore, they were not even offered screening with breast MRI which detects two to three times more cancer at an earlier stage than mammography alone, or preventive measures such as tamoxifen treatment which can cut down cancer rates by 40 to 50%.
Read More »

2 responses   |   Bookmark and Share   |   Tags: , , , , , , .

deCODE launches deCODE BreastCancer™, a genetic test to screen for risk of the most common forms of breast cancer

deCODE Breast Cancer enables women to understand whether they may benefit from more intensive screening, monitoring or preventive drug therapy.

deCODE Breast Cancer enables women to understand whether they may benefit from more intensive screening, monitoring or preventive drug therapy.

Reykjavik, ICELAND, October 8, 2008 – deCODE genetics today announced the launch of deCODE BreastCancer™, a new tool for assessing risk of the common forms of breast cancer. For the first time, a woman concerned about breast cancer can speak with her physician about a genetic test to better understand her lifetime risk of developing the common forms of the disease.

The common forms of breast cancer result from the interplay of genetic as well as environmental and lifestyle factors and represent 95 percent of all breast cancers. These are distinct from the rare and essentially purely inherited forms of the disease due to mutations in the BRCA1 and BRCA2 genes, which cause between 1 and 3 percent of breast cancers. deCODE BreastCancer™ is a DNA-based reference laboratory test performed using a simple blood sample or cheek swab, ordered by physicians on behalf of their patients.
Read More »

3 responses   |   Bookmark and Share   |   Tags: , , , , , .

Your genome, your choice: a buyer’s checklist for genetic tests

Scientists at deCODE genetics' Genetic Service Facility lab in Iceland

Scientists at deCODE genetics Genetic Service Facility lab in Iceland

The number of companies offering genetic tests to the public is large and growing. But there are vast and very real differences in the quality, purpose and price of testing services out there. So how do you tell the difference between them? And how do you decide which to use?

Knowing what you want

First and foremost, you need to think about what sort of information you hope to gain from your genome and how accurate you want the results to be. Are you taking the test only for fun, perhaps hoping to talk about your results on Facebook? Read More »

3 responses   |   Bookmark and Share   |   Tags: , , , , .

deCODE and Radboud University discover common variants in the human genome conferring risk of bladder cancer

Urinary bladder cancer is something many people have never heard of. But it is the sixth most common form of cancer in the United States, and its environmental risk factors include exposure to toxic chemicals, including some used in industrial processing as well as cigarette smoke. Genetic factors also play a role and may help to elucidate how bladder cancer starts and develops.

Today, deCODE’s cancer group and colleagues at Radboud University in the Netherlands report the discovery of two single letter variants (commonly referred to as SNPs) in the human genome that confer increased risk of bladder cancer. Both are common, and 20 percent of people of European descent carry two copies of the highest impact SNP, located on chromosome 8q24. That puts them at about 50 percent higher likelihood of developing bladder cancer than people who do not carry the variant.

Read More »

No responses yet   |   Bookmark and Share   |   Tags: , , , , , , .

Not all genetic tests are created equal

Here are a few thoughts on Nic Fleming’s piece on personal genome scans, of which one was our own, deCODEme:

Our genomes are all remarkably similar. And so it is the differences that are most interesting and important, and that make us who we are.

The same can be said of genetic testing services. We at deCODE were not at all surprised that Mr. Fleming found that he got some varying results from the three genome scans that he tried. Indeed we would be surprised (and more than a little dismayed) if he hadn’t. Analyzing the genome - accurately detecting which genetic markers individuals have at specific points in the genome, and correlating these variations with risk of a range of common diseases - has been our bread and butter for well over a decade. Read More »

3 responses   |   Bookmark and Share   |   Tags: , , , , .

New deCODE analytical tool multiplies power to discover rare genetic risk factors for common diseases

Get the Flash Player to see this player.
On Sunday, August 17, deCODE published a new statistical method for increasing the information that can be derived from high-density genotyping, leveraging the genotypic data the company has already generated
on tens of thousands of participants in its gene discovery programs. In the above video, CEO Kari Stefansson, the company’s head statistician Augustine Kong, and Chief of Communications Edward Farmer talk about how this method works and why it may help deCODE to find rarer variants conferring risk of common diseases.

Link: Read abstract in Nature Genetics

4 responses   |   Bookmark and Share   |   Tags: , , , , .

Evidence of genetic links to schizophrenia

deCODE genetics laboratory staff working on genetic research

deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia

Findings may provide the foundation for a test to complement standard clinical diagnosis, potentially enabling earlier intervention and treatment

A team of scientists led by deCODE genetics has discovered evidence of three rare deletions in the human genome that confer a greater risk of schizophrenia. This discovery shows that individuals who have one of these deletions may be up to 15 times more likely to develop schizophrenia than the population at large. See “Large recurrent microdeletions associated with schizophrenia” which appeared this afternoon in Nature (www.nature.com)

Read More »

2 responses   |   Bookmark and Share   |   Tags: , , .

deCODE on NBC Nightly News - Part 2

The second part of NBC Nightly News coverage of deCODE genetics and the genetic research conducted with the help of the Icelandic nation. Bazell continues to look at the company he sees as being at the cutting edge of genetic research.

No responses yet   |   Bookmark and Share   |   Tags: , .

deCODE research on NBC Today Show

NBC’s Robert Bazell looks at genetic research in Iceland and interviews deCODE’s CEO Dr. Kari Stefansson. Of special interest is the work carried out on common diseases that have a genetic component. Stefansson predicts that genetic tests will be widely used within 3-5 years.

No responses yet   |   Bookmark and Share   |   Tags: , , , , , .

The lowdown on deCODE

A look at deCODE, the biotech company in Iceland that is researching genes for common conditions like heart disease, stroke and cancer. Sue Herera interviews NBC’s Robert Bazell on his coverage of deCODE and discusses the scientific, pharmacological and commercial implications of genetic testing.

Originally broadcast July 22, 2008.

Link: Watch the interview.

No responses yet   |   Bookmark and Share   |   Tags: , , .

deCODE research on NBC Nightly News - Part 1


NBC chief science correspondent, Robert Bazell, reports on deCODE in Iceland. Iceland is a goldmine of genetic information. where new discoveries in genetic testing may mean a healthier life for the whole world. That Icelanders have an extensive knowledge of their ancestry, says Bazell, has been interesting for history, but now it’s very important for medicine.

No responses yet   |   Bookmark and Share   |   Tags: , , , , .

A Smoking Gene: deCODE Scientists Identify a Genetic Variant that Confers Nicotine Dependence

Scientists from deCODE genetics have identified a clear link between one genetic variant and susceptibility to nicotine dependence and will publish their results in the April 3 issue of Nature. Moreover, in part because of its impact on smoking behavior, each copy of the risk variant of this SNP confers an approximately 30% increase in risk of lung cancer and a 20% increase in risk of peripheral arterial disease (PAD), a common and debilitating constriction of the arteries to the legs.

deCODE scientists came upon the genetic variant by closely examining the genetic makeup of more than 10,000 smokers. They then followed up with an analysis of 32,000 patients and controls from Iceland, New Zealand, Austria, Sweden, Italy, the Netherlands and Spain for lung cancer and PAD, two common diseases strongly associated with smoking.

Kari Stefansson, deCODE CEO, expressed the importance of the discovery: “These findings provide an example of the power of human genetics for shedding light on the most complex health challenges. Not only have we made a convincing link between a single genetic variant and a behavioral disorder - greater smoking quantity and addiction to nicotine - but also demonstrated how this risk factor translates into risk of lung cancer and PAD.”

Stefansson also pointed out that deCODE’s genetic profile service, deCODEme, will test for the gene immediately.

Details of the smoking gene study, which was funded in part by the European Commission, and from the National Institute of Drug Abuse of the U.S. National Institutes of Health, are available at www.nature.com.

No responses yet   |   Bookmark and Share   |   Tags: , , , , .

deCODE Obesity Study Sheds Light on how Genetics Affects Risk and Onset of Common Diseases

In a paper published online today in the journal Nature, a team of deCODE scientists detail a major mechanism through which genetic factors contribute to major public health problems.

In its work on the inherited components of dozens of common diseases, deCODE has discovered gene variants that significantly affect individual susceptibility or protection against disease. In the common forms of these conditions - such as obesity, type 2 diabetes and cardiovascular diseases - deCODE has previously shown that genetic variants confer increased or decreased risk by up-regulating or down-regulating the activity of major biological pathways.

In today’s paper, the deCODE team and collaborators from Merck demonstrate one of the principal ways in which the activity of biological pathways is functionally perturbed in a quintessentially complex condition: obesity.

Kari Stefansson, CEO of deCODE, put the study into context: “One of the observations we have made in our work on the isolation of disease genes is that the genetic risk of common diseases is often conferred by variations in the sequence of the genome that affect expression of genes. Hence, one of the ways to approach the study of common diseases is through the analysis of gene expression. This paper provides a substantial contribution towards the understanding of gene expression in man and one example of how it can be used to expand our knowledge of one disease, namely obesity.”

No responses yet   |   Bookmark and Share   |   Tags: , , , .

deCODE Discovers Fourth Set of Prostate Cancer Risk Variants, Now Integrated into deCODEme™

deCODE scientists today announced the discovery of two more genetic variants linked with increased risk of prostate cancer. These variants have been integrated into the prostate cancer disease module in deCODEme™, and subscribers can check for them in their updated personal profile.

These latest SNPs are the fourth set of variants that deCODE has linked to prostate cancer risk. They are single-letter variations in the genome - SNPs - located on chromosome 2 and on the X chromosome. The SNPs confer relatively modest increases in risk - of approximately 20% and 15% per copy carried, respectively - but because they are also quite common they are each believed to contribute to about 5% of prostate cancer cases. They were found through the analysis of 300,000 SNPs in 23,000 Icelanders in deCODE’s prostate cancer studies, and then confirmed in an analysis of more than 15,500 individuals from seven different cohorts from Europe and the United States.

Published studies by major academic research groups in the United States and Europe have over the past month provided strong validation of the role of the other common risk variants, on chromosomes 8 and 17, discovered by deCODE in 2006 and 2007. Altogether, the prostate cancer risk variants now included in deCODEme™ contribute to more than 50% of all cases of the disease. Because of these variants, 10% of men are at twice the risk and 1% of men are at three times the risk of the disease in the general population.

For those subscribers who believe they should consider having a DNA-based diagnostic test for prostate cancer risk variants that they can use with their doctor, deCODE has also just launched deCODEPrCa™, the first such test aimed at understanding individual risk of the disease.

No responses yet   |   Bookmark and Share   |   Tags: , .